Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease Department of Nephrology R3. Yeehyung Kim.

Slides:



Advertisements
Similar presentations
Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia N Engl J Med Mar 11;362(10): Paul W. Ladenson, M.D., Jens D.
Advertisements

ATP III Guidelines Specific Dyslipidemias. 2 Specific Dyslipidemias: Very High LDL Cholesterol (  190 mg/dL) Causes and Diagnosis Genetic disorders –Monogenic.
CHOLESTEROL AND OUR LIVES الدهنيات وحياتنا
Robert K Huff PharmD. Candidate May Objectives The study was designed to examine 3 main aspects Biochemical effects Safety Tolerability Evacetrapib.
Lipid Disorders and Management in Diabetes
Canadian Diabetes Association Clinical Practice Guidelines Dyslipidemia Chapter 24 G. B. John Mancini, Robert A. Hegele, Lawrence A. Leiter.
Lipids 101 Cardiology Board Review Med-Peds Style!
Final Exam Tuesday, 6/5, 2 PM Closed book – Essay and MC/TF Determining Energy Needs – p – Indirect calorimetry – Be able to do the calculations.
Diagnosis and Treatment of Dyslipidemia  New guidelines are based on the “Adult Treatment Plan III (ATP III)” 2004  Focus = multiple risk factor assessment.
Treatment of Dyslipidemia SDPI CGP Healthy Heart Project March 8, 2006.
LDL Cholesterol Goals and Cutpoints for Therapeutic Lifestyle Changes (TLC) and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL)
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 50 Prophylaxis of Coronary Heart Disease: Drugs That Help Normalize Cholesterol.
DYSLIPIDEMIA IN ADULTS WITH DIABETES* 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada *Updated in Leiter.
APPENDIX 1. D-1 New cases of diagnosed diabetes D-2.1 All cause mortality* D-2.2 Cardiovascular disease deaths* D-3 Diabetes death rate, multiple cause.
Adult Treatment Panel III (ATP III) Guidelines
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Update Lipid Management in Chronic Kidney Disease 成大醫院心臟內科 李政翰醫師 助理教授.
Hyperlipidemia John Baer.
Department of Family & Community Medicine
Antidislipidemic drugs ( Summary ) © Dr Ivan Lambev, PhD Medical University of Sofia, Faculty of Medicine Department.
Hperlipidemia:- Treatment and Management Presented by:- Dr. Tewari.
Antihyperlipidemia.
Fenofibrate Intervention and Event Lowering in Diabetes FIELDFIELD Presented at The American Heart Association Scientific Sessions, November 2005 Presented.
Dyslipidemia: What Every Resident Should Know
Dyslipidemia.  Dyslipidemia is elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high- density lipoprotein level that contributes.
Case 15 Andrea De Mesa. Patient history A 44 y/o male, single, undergoes cardiovascular screening on advice of his attending physician. He is a smoker.
Chapter 19 Agents Used to Treat Hyperlipidemia. Hyperlipidemia 2 Atherosclerosis – accumulation of fatty substances on the inner wall of large and medium.
This lecture was conducted during the Nephrology Unit Grand Ground by Nephrology Registrar under Nephrology Division, Department of Medicine in King Saud.
HYPERLIPIDEMIA Applied Therapeutics Dr. Riyadh Mustafa Al-Salih.
HLD Tx & AHA/ACC Guidelines
Adult Treatment Panel III (ATP III) Guidelines Hyperlipidemia.
ACC/AHA Guidelines Not the Final or Only Word. Contemporary Guidelines
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Scott W. Rypkema, M.D.
Cholesterol Measurement All adults should have their blood cholesterol measured every 5 years May be in non-fasting state Fasting preferred
Prophylaxis of Coronary Heart Disease: Drugs That Help Normalize Cholesterol and Triglyceride Levels.
1 A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and Dyslipidemia Diabetes Care 28:1547–1554,
The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent.
Dyslipidemia in Chronic Kidney Disease
Dyslipidemia after Kidney Transplant
Copyright © 2015 by the American Osteopathic Association.
Therapeutic Lifestyle
Drugs for Lipid Disorders
Anti-Hypercholesterolemic Agents
By: Dr Israa Omar MBBS, MRCP, MSc pharmacology
Copyright © 2012 American Medical Association. All rights reserved.
Lipoprotein(a), Cardiovascular Disease, and Contemporary Management
National Cholesterol Education Program
Classification of total cholesterol levels
AIM-HIGH Niacin Plus Statin to Prevent Vascular Events
FATS- Familial Atherosclerosis Treatment Study
Antilipidaemic agents
An Endocrinology Clinic in Dyslipidemia
Back to the Basics of Dyslipidemia
Patients aged 85yrs and over
Diabetes Dr. J. Antony Gagnon, Pharm.D., CDE, CAE
Type 2 diabetes: Overlap of clinical conditions
Rational Order of Laboratory Tests in Cardiovascular Diseases
I. Introduction American Journal of Kidney Diseases
LRC-CPPT and MRFIT Content Points:
Goals & Guidelines A summary of international guidelines for CHD
Major classes of drugs to reduce lipids
Opening a New Lipid “Apo-thecary”: Incorporating Apolipoproteins as Potential Risk Factors and Treatment Targets to Reduce Cardiovascular Risk  Terry.
60 yo white female Former smoker x 20 years Father had MI at age 42.
III. Treating dyslipidemias
Lipids, the Heart, and the Kidney
Dyslipidemia And Diabetes
ATP III Guidelines Drug Therapy FUTURE RESEARCH.
Section 6: Update on lipid treatment guidelines
ATP III Guidelines Benefit Beyond LDL-Lowering:
Specific Dyslipidemias: Very High LDL Cholesterol (>190 mg/dL)
Presentation transcript:

Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease Department of Nephrology R3. Yeehyung Kim

Causes of death among period prevalent patients 1997–1999, treated with hemodialysis, peritoneal dialysis, or kidney transplantation. Introduction

 The National Kidney Foundation (NKF) Task Force on CVD Incidence of ACVD is higher in patients with CKD compared to the general population CKD : considered to be in the highest risk category  NKF Kidney Disease Outcomes Quality Initiative (K/DOQI) CKD : considered a CHD risk equivalent risk factors should be managed accordingly  Dyslipidemias may play a major role for ACVD in patients with CKD

The definitions of dyslipidemias adopted by the Work Group were those of ATP III

 No randomized controlled intervention trials in CKD patients Treatment of dyslipidemias reduces incidence of ACVD…?  Work Group concluded that additional, randomized, placebo- controlled trials are urgently needed in patients with CKD  Target population for guidelines on the Mx. of dyslipidemia Stage 1~5 CKD pt All renal transplant recipients : at increased risk for CKD CKD individuals 18–20 : included and considered as adults Adolescents or children at any stage of CKD

 Guideline 1. All adults and adolescents with CKD should be evaluated for dyslipidemias. (B) The assessment of dyslipidemias should include a complete fasting lipid profile with total cholesterol, LDL, HDL, and triglycerides. (B) All of the major treatment decisions for dyslipidemia based on levels of triglycerides, LDL, and non-HDL cholesterol. For adults and adolescents with Stage 5 CKD, dyslipidemias should be evaluated upon presentation (when the patient is stable) at 2–3 months after a change in treatment or other conditions known to cause dyslipidemias changes in kidney replacement therapy modality, treatment with diet or lipid- lowering agents, immunosuppressive agents that affect lipids (eg, prednisone, cyclosporine, or sirolimus) or other changes that may affect plasma lipids. At least annually thereafter. (B) Assessment of Dyslipidemia

 Guideline 2. For adults and adolescents with Stage 5 CKD, a complete lipid profile should be measured after an overnight fast whenever possible. (B) Hemodialysis patients should have lipid profiles measured either before dialysis, or on days not receiving dialysis. (B) Hemodialysis : acutely alter plasma lipid levels d/t hemoconcerntration or effect of dialysis membrane or heparin on lipoprotein metabolism Few data describing how quickly lipoprotein levels change during the course of PD Assessment of Dyslipidemia

 Guideline 3. Stage 5 CKD patients with dyslipidemias should be evaluated for remediable, secondary causes. (B) Assessment of Dyslipidemia

Treatment of Dyslipidemia The approach to treatment of dyslipidemias in adults with CKD high levels of LDL are the focus of treatment To prevention of pancreatitis

 Guideline 4. For adults with Stage 5 CKD & fasting triglycerides 500 mg/dL that cannot be corrected by removing an underlying cause treatment with therapeutic lifestyle changes (TLC) and a triglyceride-lowering agent should be considered. (C) For adults with Stage 5 CKD & LDL > 100 mg/dL Treatment should be considered to reduce LDL to <100 mg/dL For adults with Stage 5 CKD and LDL <100 mg/dL fasting triglycerides > 200 & non-HDL cholesterol > 130 mg/dL Treatment should be considered to reduce non-HDL cholesterol to <130 mg/dL

Treatment of Dyslipidemia The approach to treatment of dyslipidemias in adolescents with CKD

 Treating Proteinuria Nephrotic range proteinuria Total & LDL-cholesterol ↑ Severe case  TG ↑ Remission in nephrotic syndrome, reduction of proteinuria by ARBs or ACEi Improvement of lipid-profile…? Unfortunately, few randomized controlled trials have documented the lipid-lowering effects of therapies that reduce urine protein excretion Treatment of Dyslipidemia

Therapeutic lifestyle change (TLC) for Adult with CKD

The Use of Statins in Patients Receiving Cyclosporine or Tacrolimus  Cyclosporine increase the blood levels of virtually every statin  The degree that levels are altered dependent on differences in the metabolic pathways of the different statins.  The cytochrome P450 3A4 enzyme important in the metabolism of lovastatin, simvastatin & atorvastatin inhibited by cyclosporine.  Fluvastatin : metabolized bythe cytochrome P-450 2C9 pathway  Pravastatin : not rely on the cytochrome P-450 system

Avoiding Agents That Increase the Blood Levels of Statins  Most medications that are well documented to increase statin blood levels are metabolized by the hepatic cytochrome P450 enzyme superfamily macrolide antibiotics azole antifungal agents calcium-channel blockers Fibrates & nicotinic acid serotonin re-uptake inhibitors Warfarin grapefruit juice

Adding a Second LDL-Lowering Agent to a Statin  In general, it is probably wise to avoid the use of a fibrate together with a statin in CRD  Bile acid sequestrants Can be used in combination with a statin Few studies of the safety and efficacy in patients with CKD Cholestyramine, colestipol, and colesevelam hydrochloride Contraindicated in patients with triglycerides > 400 mg/dL increase triglycerides in some patients. new phosphate-binding agent, sevelamer hydrochloride appears to lower lipid levels  Nicotinic acid Alternative 2 nd agent in combination of statin No data about combination use in CRD

The Use of Bile Acid Sequestrants in Kidney Transplant Recipients  interfere with the absorption of immunosuppressive medications  Based on these very limited data bile acid sequestrants may not have a major effect on cyclosporine absorption No published data on the effects of bile acid sequestrants on other immunosuppressive agents  It is probably best to avoid taking the bile acid sequestrant at the same time as any other medication, if this is possible.

Optimizing Immunosuppressive Agents in Kidney Transplant Recipients  In deciding to change or not to change immunosuppressive agents, the risk of rejection should be weighed against the risk of ACVD  Transplant recipients who are diabetic and/or have known ACVD More to gain from changing immunosuppressive agents than patients at lower risk for ACVD

Rationale for Treating Non-HDL Cholesterol in Patients With High Triglycerides  low HDL, high TG & increased non-HDL cholesterol Part of a metabolic syndrome (insulin resistance, obesity, hypertension, and dyslipidemia) that is associated with ACVD  Recent data … non-HDL cholesterol may actually be a better predictor of coronary mortality than LDL reasonable surrogate marker for apolipoprotein B (atherogenic lipoproteins) TG < 200, non-HDL cholesterol correlates best with LDL